Type-1 inhibitor of plasminogen activators Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies by Munch, Mette et al.
Volume 293, number 12.3. 102-106 FEBS 10318 
Q 1991 Fcdcration of European Biochemical Socictics 00145793i9liS3.50 
December 1991 
Distinction between latent, activated and reactive centre-cleaved forms with 
thermal stability and monoclonal antibodies 
Mette Munch. Christian Heegaard, Paul H. Jensen* and Peter A. Andreasen 
Received 23 September 1991 
Type-l inhibitor oTplasminogcn activalors (PAI-I) occurs in purified preparations in a latenr form thal can be activated with dcnaturants; in vivo, 
Iiltency is prevented by binding to vitroncctin. WC have compared latent, dcnaturant-actiwcd and rcactivcccntrc-clcavcd human PAL1 with respect 
to thermal stability and affinity to monoclonal antibodies. By both criteria. latent and cleaved PAI-I are very similar or indistinguishable. and clearly 
diKerent rrom active PAI-I. Our tindings suggest that the conformations or latent and reactive ccntre-clcavcd PAI-I arc similar and rcsemblc the 
so-called relaxed (R) serpin conformation, while that oT active PAI-I is different and rcscmbles the stressed (S) scrpin conrormation. 
Scrpin; P!asminogcn acti?:atcr; Pp.!-! ; %inc protcizsc 
I. INTRODUCTION 
The serpins constitute a superfamily of extracellular 
glycoproteins, many of which are inhibitors of serine 
proteinases. They expose at their surface a 20 amino- 
acid-long peptide segment, situated near the C- 
terminus. In the inhibitory serpins, this segment con- 
tains a peptide bond called the reactive cent:e, between 
amino acids denoted P, and P,‘. Proteinase interaction 
with the reactive centre leads to the formation of a 1:l 
stoichiometric complex. Treatment of the complexes 
with nucleophilic agents under denaturing conditions 
results in the dissociation and release of reactive centre- 
cleaved, inactive inhibitors. In non-inhibitory serpins, 
for instance ovalbumin, the exposed reactive centre seg- 
ment analogue is particularly susceptible to proteolytic 
cleavage [ 11. 
The X-ray crystal structures of reactive centre- 
cleaved a,-proteinase inhibitor (a,-PI) [2], native oval- 
bumin [3], elastase-cleaved ovalbumin (plakalbumin) [4] 
and reactive centre-cleaved a,-antichymotrypsin [5] 
have been determined. Based on sequence alignment of 
different serpins [ 11, these three-dimensional structures 
may be used for discussion of the three-dimensional 
structures of serpins in general. In native ovalburnin, 
the reactive centre segment is exposed and separated 
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from the main body of the molecule; N-terminally, it is 
connected to strand 5 of a large central P-sheet termed 
A. In cleaved a,-PI and a,-antichymotrypsin, the pep- 
tide segment Pi-PIs is inserted as strand 4 of P-sheet A. 
In contrast, in cleaved ovalbumin, the liberated segment 
remains exposed (see Fig. 1). 
Reactive centre-cleavage of inhibitory scrpins is as- 
sociated with a marked increase in thermal stability (in 
the sense of an increase in solubility at elevated 
temperatures) and changes in spectroscopic properties 
[6-91. The conformational rorms before and after 
cleavage have been termed stressed (S) and relaxed (K), 
respectively. In contrast, cleavage of ovalbumin does 
not lead to such changes [7,10,1 11. Thus, conversion of 
the S to the R conformation appears to be closely 
coupled to the presence of the segment P,-P,5 as strand 
4 ofP-sheet A. 
Type-l inhibitor of plasminogen activators (PAI-1) is 
a member of the serpin superfamily [12,13]. When 
purified, it appears in a latent form with a very low 
specific inhibitory activity. Latent PAI- can be ac- 
tivated by exposure to denaturants [14,15]. The active 
state of PAI-I can be maintained by binding to vitro- 
nectin [16-201. The molecular mechanism behind the 
latency of PAI-I is unknown. In the present com- 
munication, we attempt to relate the latency of PAI- 
to the notion of 5’ and R serpin conformations. 
2. MATERIALS AND METHODS 
2. I. Proreirrs NM/ urrrihorlics 
Human PAI-I was purified from strum-free conditioned medium 
ol’dcxamc~hasonc-treated MT-1080 cells by immunoallinity chroma- 
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mM Na,HPO,. pH 7.4.0.15 M NaCI (phosphalc-buTTered saline. PBS) 
and conccntralcd IO 500-1200 @ml by rhc use of a Sartorius col- 
lodiou &g at 4’C. It was stored in aliquots at -8OOC. Thawrd aliquois 
wcrc not rcrrozcn but discarded. 
PAI-I was activated with guanidinium hydrochloride by mixing 
stock solutions with an equal volume of 8 M guanidinium hydro- 
chloride and incubating the mixlure at room temperature for 2 h. The 
guanidinium hydrochloride was removed by an overnight dialysis 
against PBS. 
PAI-I was aclivaicd with SDS by incuba@ slack solutions with 
0.1% SDS for I h at room temperalure: the SDS was then quenched 
by the addition of Triion X-100 IO a conccmration of I% and A more 
than IO-Told dilution with bulTcr with 0.1% Triton X-100. 
Reactive ccnlrc-clcavagc was pcrrormed by incubalinr undiluted 
SDS-aclivarcd PAI-I (that is.containingO.l% SDS. I%Tr%on X-100) 
will1 human ,u-PA (Scrono. Switzerland) at a concentration of 0.5 
,ugniml for4 II at 37°C [22.23]. Thiswas FoRowed by a more than IO-fold 
dilurion with burlizr with O.l%Trhon X-100. In somccdscs. PAI-I was 
cleaved before purification. dircclly in ~hc conditioned medium. SDS- 
aclivation and p-PA rrcatmcnt (as above) were followed by purifica- 
tion as above. only will1 an cstra wash wilh 0.1 M Tris. pH 8.1. 1% 
T&on X-100, in order IO ensure complclc removal ol SDS. 
3 clones of hybridomas producing anti-human PAI-I I@, tcrmcd 
clones l-3. were those described previously [Sl]. Hybridoma clone 5 
rcsuilcd from an indcpcndcnt inlmunizttion a& iusion [h’iclscn. L.S. 
and Audrcascn. P.A., unpublished]. Polyclonal rabbit anti-human 
PAI-I IgG was as bcf’orc [24]. 
TIIC dilTercm forms or PAI-I wcrc incubated al the indicated 
reinpcraturcs l-or 2 h a~ a conccmration oT75~&ml. AIicr incubation. 
the samples were cooled on ice and centrirugcd at 20 000 xg. Aliquols 
corresponding 10 IOflu~. PAI-I wcrc iaken from the supcrnalants and 
subjected IO SDS-PAGE in gels with IO’% polyacrylamidc. Coomassic 
blue-siaincd gels wcrc scanned spcctrophotomelrically will] a 
Shimadzu Dual Wavelength Scanner CS930. 
To ICSI ihc binding or diITcrenl PAI-I forms IO monoclonal an& 
bodies. the various monoclonal antibodies wcrc coated omo the solid 
plusc. A layer oT PAI-I in various conccrurations was rollowed by a 
layer or polyclonal rabbi1 amGAl- IgG and a layer of pcronidasc- 
conjugalcd swine IgG against rabbit IgG. To lest for diffcrcnccs in 
cphopcs bclwccn monoclonal an&PAI-I I@ from diffcrcni hy- 
bridoma clones. the solid-phase anlibody was monoclonal I&i from 
OIIC or the various hybridoma cioncs, as above. A layer of PAI-I in 
various concentrations was followed by ;I layer of biolin-labcllcd 
monoclonal IgG from one or the various hybridoma clones and a layer 
of nvidin-pcroxidasc. The mumbcrs or pairs oT amibodics showing 
compdtibilily of binding wcrc scored as having diffcrcm cpilopcs. 
Oilier dclails oT IIIC ELlSAs wcrc as dcscribcd carlicr [25]. 
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plakalbumin ;Ind clcavcd a,-PI. Al. plakalbumin; A3. B. C and D. 
mcIivc ccnwclcavcd q-PI. The pcptidc scgmcn~ spanning lhc I5 
amino acids S-terminal IO the rcactivc ccnlcr (PI-P,,) is shaded in A. 
NOIC Ihat 6 ;IIII~IUJ acids (PI-P,,) have been clcavcd from plakalbumin 
by the clas~;~se trcatmcnt. The secondary structural clcmcnls indicalcd 
in B, C and Dare those cxpcc~cd IO coniain the cphopcs Tar molioclo- 
nal an&PAI-I imlibodics from hybridoma clone 2 (B); from clone 3 
(C); and drool clone 5 (D), respcciivcly. under IIIC assumption ihai 
a,-PI und PAI-I contain the same secondary slruciural clcmcnls. h = 
a-helix, s = slrdnd in ~/~-~IIccI. The stereoscopic drawings arc adapicd 
from Wright CI al. [4]. wiih permission. For further details abour the 
cpitopcs, see Table I. 
lography on a column or Scpharosc 4B coupled whh monoclonal 
murinc anti-human PAI-I IgG Tram hybridoma clone 2 [al]. Im- 
mcdiatcly alier purilicalion, IIIC prcparalion was dialysed against IO 
3. RESULTS 
We characterized latent, activated and reactive 
centre-cleaved PAI- by thermal stability in the sense of 
solubility at a given temperature. Cleaved PAI-I 
remained in solution at temperatures up to 90°C (Fig. 
2C). In contrast, guanidinium hydrochloride- and SDS- 
activated PAI- was labile at temperatures above 40°C 
(Fig. 2B). Latent PAI-I was, when incubated at 
temperatures above 4O”C, partially converted to 3 types 
of aggregates migrating in SDS-PAGE corresponding 
to M, of approximately 85 000, 107 000 and I20 000, 
respectively. However. the total amount of protein seen 
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Fig. 2. Thermal stability of different form of PAI-I. The different 
forms of PAI- was incubated at various tcmpcratures for ?. h. If not 
othcrwirc indicated, IIIC buffer \vas 0. I M Tris-HCI pH 8.1. 0. I% 
Triton X-100. Artcr incubalion. cooling on ice and ccntrifuga~ion. the 
anlount ol’ PAI-I rcinaining in solution was analysed by SDS-PAGE 
ml Coomassic blue straining (top part or the figure). The gels wcrc 
swmcd spectrophotomctrically (bottom part or the ligurc). For each 
PAI-I form. the amounts l’ound on ~hc & aticr the incubations wcrc 
csprcsscd as a pcrccntagc of that found in a sample kept at 0°C 
(bottom part of figure). A: Latent PAI-I. (a). dl, 54 000 band: (c). 
bighcr .\I, bends: (7). sum of all bands. B: Activated PAI-1. (C), 
puanidinium hydrocbloridc-activated. PAI-I; (0). SDS-aciivatcd PAI- 
I (linal SDS-conccntrntion durin_c the incilbahns 0.006%. final Tri- 
IOII X-100 conccntraiion 0.1684). The gel shows guanidinium hy- 
drochloridc-activated PAI-I. C: Clcavod PAI-I. (0). PAI-I clcavcd 
aticr purtication (final SDS concentration during the incubations 
O.OIOc/c. final Triton X-100 coaccntn~tionO.l91%): (?). PAI-I clcawd 
in the conditioned medium before purificalion; there was no SDS 
prwnt dcring the incubations. hIcan and standard deviation arc 
indicotcd. The number of dctcrminations wcrc bctwccn 3 and 4. The 
SDS and the additional Triton X-100 in SDS-activated PAI- and one 
ol‘thc preparations ofclcnvcd PAI-I were carried over from the SDS- 
activarion. The idcntiry of the results obtained with !, PAI-I clcavcd 
bciorc and slier purification. and 2. PM-I activated wilh SDS a~?d 
guanidinium !Iydr...,,,v,, nol*lnr:dc. dcmonstratc that thcsc small amounts or 
SDS did not inllucncc tllc results obtuir.cd. Separate control cxpcri. 
I~ICII~S (not shown) dcmonstratcd that SDS in ~hesc low concentration:; 
also did not affect the ihr:.mal stability of hen1 PM-I. 
on the gels remained almost constant at all temperatures 
(Fig. 2A). Also, latent PAI-I migrated in gel filtration 
0;; a Superose !2!-IR-co!umn (PBS, room !e:!$?erature) 
as a single, sharp peak to the same position as oval- 
bumin (not shown), indicating the absence of aggrega- 
tion at lower temperatures. Activated PAI-I migrated 
into the same position. 
3.2. Rcuclivity with ttrottoclottul ttttribodics 
We used 4 monoclonal anti-human DAI-I antibodies. 
The epitopes for 3 of the antibodies have been localized 
to certain stretches of the polypeptide chain [26], By the 
use of the three-dimensional struciure of cleaved ccl-PI 
[2], and the sequence oi!gnmcnt of different serpills 
given by Huber and Carrel1 [I], these epitopcs may be 
assigned to different secondary structural elements 
which, due to the strong sequence homology, arc ex- 
Table I 
Propcrtics or tnurinc monoclonal antibodies against human PM-I 
Hybridonia clone. no. Epitopc. Ephopc, secondary 
amino acids slructUriil clcmciiis 
I 
?. 
3 
5 
- 
not linear 
I IO-145 
W-283 
2?4--295 
hE. slA. hF 
s3B. IIG. hH. QC, 
SAA 
s6A. Ill 
‘h’ dcnotcs an a-helix and ‘s’ ;I strand in a b-sheet. The numbering or 
the secondary structural clcmcnts is that given by Lijbcrmann ct al. 
[2]. Their loc;uions arc indicated in Fig. I. See 111~ cxt ror hlrthcr 
explanation. 
petted to exist in both PAI-I and al-PI (Table I). Anti- 
bodies from clone 2. and from clones 3 and 5, respec- 
tively, are seen to bind to epitopes localized on opposite 
faces of the molecule (Fig. I). The epitope for antibodies 
from clone I could not be assigned to a distinct. linear 
area of PAI-I. We also found, by ELISA, that any pair 
of the 4 antibodies was able to bind al the same time 
(data not shown), and thus all antibodies have differen 
epitopes. 
The binding of latent, nctivated and reactive centre- 
cleaved PAI-I to the monoclonal antibodies was tested 
by ELISA. IgG from clone 2 reacted identically with the 
different forms (not sl~own). With IgG from hybridoma 
clones 3 and 5, the binding to latent PAI-I was weak, 
but increased strongly upon activation, while it de- 
creased to the level of the latent form upon reactive 
centre-cleavage. With IgG from hybridoma clone I. the 
affinity changed in the reverse manner (Fig. 3). Testing 
the binding over a wider PAI- I concentration range (noi 
shown), the difference was found to be 5-fold in the case 
of IgG from clone I. and more then IOO-fold with IgG 
from clones 3 and 5. 
[PAI-11. nglml 
Fig. 3. Binding of difrcrcnt forms of PAI-I to monoclonal IgG. The 
binding of Iatcnt (0). SDSactivatcd (0). guanidinium hydrochloridc- 
activated (C),and rcactivcccntrc-clcavcd PAI-I (V) LO anti-PAI-I IgG 
from hybridoma clone I, clone 3 and clone 5 WIS mcasurcd by ELISA. 
The concentrations of PAI-I in the assay wells arc indicated on the 
abscissa. and the resulting optical density at 490 nm iIt the ordinate. 
The buffer was PBS with 0.01% Twccn 20. Small mnu~m or SDS 
(<O.OOOl%) wcrs carried over from the stock solutions of SDS-ncti- 
vatcd itnd cleaved PAI-I. The possibility for an cffcct oi this directly 
on binding ws excluded by adding similar amount of SDS IO latent 
nnd guanidiniutn hydrocbloridc activated PM-I, lhc only dil7crcncc 
being that IhcTriton X-100 used to quench the SDS Was added bcforc 
SDS ill thcsc cases. 
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4. DlSCUSSlON 
Our finding of a high thermal stability of reactive 
centre-cleaved PAI-I shows that this is in the R-con- 
formation, and suggests that reactive ccntre-cleavage is 
associated with expansion of P-sheet A by a sixth 
strand, consisting of amino acids P,-P,5, also in this 
serpin. In contrast, activated PAI-I appears to be in the 
S conformation like the native forms of other inhibitory 
serpins. The thermal stability of latent PAI-I suggests 
that this form is also in an R-like conformation. The 
similarity between latent and cleaved PAI-I is sub- 
stantiated by their reactivity with monoclonal antibod- 
ies, by which criterion they are indistinguishable and 
clearly different from activated PAI-1. On the basis of 
this similarity, one may speculate that the peptide seg- 
ment P,-P,> is partially inserted intoP-sheet A in latent 
PAI- I. As pointed out by Stein et al. [3]. a partial inser- 
tion is possible. due to the fact that the reactive centre 
loop is partly in the form of an extensible a-helix. A 
partial insertion could result in the reactive centre seg- 
ment becoming inaccessible to the proteinase by placing 
the uninserted part of it very close to the main body of 
the molecule. This proposal is in agreement with recent 
findings of Schulze et al. [27] showing that a peptide 
corresponding to P,-P,< of cr,-Pl can convert native 
q-PI to a form resetnbl& the reactive ccntre-cleaved 
form by several physicochemical parameters. 
The tendency of latent PAI-I to form aggregates at 
high temperatures uggests that differences do exist be- 
tween the conformations of latent and cleaved PAI-I. 
since the latter dots not form aggregates. However. 
there were no indications of aggregation at lower 
temperatures, neither by SDS-PAGE nor gel liltration, 
and latent PAI-I migrated in the same position as ac- 
tivated PAI-I in gel filtration. This shows that the ob- 
served properties of latent PAI-I is not determined by 
its tendency to form eegregates. 
The cpitopes for ant:-PAI-I antibodies from clones 3 
and 5. which are most exposed in the activated form, are 
seen to be present in regions of the molecule that may 
possibly be affected by changes concerning P-sheet A. 
T!x region contains strand hA, a member of this,Lf-sheet 
(see Fig. I). In addition. the region contains strand 2C 
with Lys”‘” (I+‘“0 in a,-PI), which appears to form a 
salt bridge to GILI”:’ (Glu3” in a,-PI); CiluJ” is at the 
pivot point at the insertion of strand 4A into P-sheet A 
[I]. Antibodies from clone 2 are not conformntion-sensi- 
rive. although their cpitope is locaiized to a region in 
proximity to/l-sheet A. The epitope for antibodies from 
clone I, which is most exposed in the latent and cleaved 
forms, is probably formed by amino acids from differ- 
ent parts of the polypeptide chain, but it does not ovcr- 
lap with those of antibodies from the three other clones. 
The cpitopes tested in the present work represents 
most of the cpitopes found for monoclonal antibodies 
from a number of laboratories [26]. It may bc of interest 
to test if antibodies with other epitopes, produced for 
instance by immunization with peptides, are sensitive to 
other conformational changes. 
In vivo. vitronectin appears to function as a cofactor 
for PAI-I, stabilizing it in an active conformation [l7-- 
211. Extending the above proposal, the function of vitro- 
nectin would be to prevent the partial insertion of the 
intact reactive centre segment into the central B-sheet. 
thereby keeping it accessible to the proteinase. 
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